Tags : Remdesivir

COVID-19 Pharma

Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19

Shots: Mylan launches Desrem (remdesivir) addressing the unmet needs amid COVID-19. The drug is approved for the treatment of suspected or laboratory-confirmed incidences of COVID-19 in adults and children hospitalized with severe symptoms Mylan will manufacture Desrem in its state-of-the-art injectable facility in Bangalore, India, and other export markets where Mylan has received a license […]Read More

COVID-19 Pharma

EMA Anticipates the EC’s Conditional Marketing Authorization for Gilead’s Remdesivir

Shots: EMA’s CHMP has recommended conditional marketing authorization to Veklury (remdesivir) for the treatment of COVID-19 in adults and adolescents aged ≥12yrs. with pneumonia who require supplemental oxygen, making it the first treatment to be approved in EU EMA expects the EC to grant conditional marketing authorization for remdesivir next week using a fast-track process, […]Read More

COVID-19 Pharma

Gilead to Initiate P-II/III Study Evaluating Remdesivir in Pediatric Patients

Shots: Gilead will begin enrollment in P-II/III clinical trial assessing the safety, tolerability, PK and efficacy of remdesivir in ~50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents The trial will be conducted at 30+ sites in the US and EU. Remdesivir is available to pediatric patients with severe COVID-19 under our compassionate use […]Read More